Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques

Thomas A. Waldmann, Enrico Lugli, Mario Roederer, Liyanage P. Perera, Jeremy Smedley, Rhonda MacAllister, Carolyn K. Goldman, Bonita R. Bryant, Jean M. Decker, Thomas A. Fleisher, H. Clifford Lane, Michael C. Sneller, Roger J. Kurlander, David E. Kleiner, John M. Pletcher, William D. Figg, Jason L. Yovandich, Stephen P. Creekmore

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

IL-15 uses the heterotrimeric receptor IL-2/IL-15Rβ and the γ chain shared with IL-2 and the cytokine-specific IL-15Rα. Although IL-15 shares actions with IL-2 that include activation of natural killer (NK) and CD8 T cells, IL-15 is not associated with capillary leak syndrome, activation-induced cell death, or with a major effect on the number of functional regulatory T cells. To prepare for human trials to determine whether IL-15 is superior to IL-2 in cancer therapy, recombinant human IL-15 (rhIL-15) was produced under current good manufacturing practices. A safety study in rhesus macaques was performed in 4 groups of 6 animals each that received vehicle diluent control or rhIL-15 at 10, 20, or 50 μg/kg/d IV for 12 days. The major toxicity was grade 3/4 transient neutropenia. Bone marrow examinations demonstrated increased marrow cellularity, including cells of the neutrophil series. Furthermore, neutrophils were observed in sinusoids of enlarged livers and spleens, suggesting that IL-15 mediated neutrophil redistribution from the circulation to tissues. The observation that IL-15 administration was associated with increased numbers of circulating NK and CD8 central and effector-memory T cells, in conjunction with efficacy studies in murine tumor models, supports the use of multiple daily infusions of rhIL-15 in patients with metastatic malignancies.

Original languageEnglish (US)
Pages (from-to)4787-4795
Number of pages9
JournalBlood
Volume117
Issue number18
DOIs
StatePublished - May 5 2011
Externally publishedYes

Fingerprint

Interleukin-15
Pharmacokinetics
Immune system
Macaca mulatta
Toxicity
Immune System
Safety
T-cells
Interleukin-2
Neutrophils
Capillary Leak Syndrome
Chemical activation
Bone Marrow Examination
Neoplasms
Natural Killer T-Cells
Hepatomegaly
Interleukin-2 Receptors
Splenomegaly
Cell death
Regulatory T-Lymphocytes

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. / Waldmann, Thomas A.; Lugli, Enrico; Roederer, Mario; Perera, Liyanage P.; Smedley, Jeremy; MacAllister, Rhonda; Goldman, Carolyn K.; Bryant, Bonita R.; Decker, Jean M.; Fleisher, Thomas A.; Lane, H. Clifford; Sneller, Michael C.; Kurlander, Roger J.; Kleiner, David E.; Pletcher, John M.; Figg, William D.; Yovandich, Jason L.; Creekmore, Stephen P.

In: Blood, Vol. 117, No. 18, 05.05.2011, p. 4787-4795.

Research output: Contribution to journalArticle

Waldmann, TA, Lugli, E, Roederer, M, Perera, LP, Smedley, J, MacAllister, R, Goldman, CK, Bryant, BR, Decker, JM, Fleisher, TA, Lane, HC, Sneller, MC, Kurlander, RJ, Kleiner, DE, Pletcher, JM, Figg, WD, Yovandich, JL & Creekmore, SP 2011, 'Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques', Blood, vol. 117, no. 18, pp. 4787-4795. https://doi.org/10.1182/blood-2010-10-311456
Waldmann, Thomas A. ; Lugli, Enrico ; Roederer, Mario ; Perera, Liyanage P. ; Smedley, Jeremy ; MacAllister, Rhonda ; Goldman, Carolyn K. ; Bryant, Bonita R. ; Decker, Jean M. ; Fleisher, Thomas A. ; Lane, H. Clifford ; Sneller, Michael C. ; Kurlander, Roger J. ; Kleiner, David E. ; Pletcher, John M. ; Figg, William D. ; Yovandich, Jason L. ; Creekmore, Stephen P. / Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. In: Blood. 2011 ; Vol. 117, No. 18. pp. 4787-4795.
@article{58f6f3d2221a44fcbcfaf11751eedc23,
title = "Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques",
abstract = "IL-15 uses the heterotrimeric receptor IL-2/IL-15Rβ and the γ chain shared with IL-2 and the cytokine-specific IL-15Rα. Although IL-15 shares actions with IL-2 that include activation of natural killer (NK) and CD8 T cells, IL-15 is not associated with capillary leak syndrome, activation-induced cell death, or with a major effect on the number of functional regulatory T cells. To prepare for human trials to determine whether IL-15 is superior to IL-2 in cancer therapy, recombinant human IL-15 (rhIL-15) was produced under current good manufacturing practices. A safety study in rhesus macaques was performed in 4 groups of 6 animals each that received vehicle diluent control or rhIL-15 at 10, 20, or 50 μg/kg/d IV for 12 days. The major toxicity was grade 3/4 transient neutropenia. Bone marrow examinations demonstrated increased marrow cellularity, including cells of the neutrophil series. Furthermore, neutrophils were observed in sinusoids of enlarged livers and spleens, suggesting that IL-15 mediated neutrophil redistribution from the circulation to tissues. The observation that IL-15 administration was associated with increased numbers of circulating NK and CD8 central and effector-memory T cells, in conjunction with efficacy studies in murine tumor models, supports the use of multiple daily infusions of rhIL-15 in patients with metastatic malignancies.",
author = "Waldmann, {Thomas A.} and Enrico Lugli and Mario Roederer and Perera, {Liyanage P.} and Jeremy Smedley and Rhonda MacAllister and Goldman, {Carolyn K.} and Bryant, {Bonita R.} and Decker, {Jean M.} and Fleisher, {Thomas A.} and Lane, {H. Clifford} and Sneller, {Michael C.} and Kurlander, {Roger J.} and Kleiner, {David E.} and Pletcher, {John M.} and Figg, {William D.} and Yovandich, {Jason L.} and Creekmore, {Stephen P.}",
year = "2011",
month = "5",
day = "5",
doi = "10.1182/blood-2010-10-311456",
language = "English (US)",
volume = "117",
pages = "4787--4795",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "18",

}

TY - JOUR

T1 - Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques

AU - Waldmann, Thomas A.

AU - Lugli, Enrico

AU - Roederer, Mario

AU - Perera, Liyanage P.

AU - Smedley, Jeremy

AU - MacAllister, Rhonda

AU - Goldman, Carolyn K.

AU - Bryant, Bonita R.

AU - Decker, Jean M.

AU - Fleisher, Thomas A.

AU - Lane, H. Clifford

AU - Sneller, Michael C.

AU - Kurlander, Roger J.

AU - Kleiner, David E.

AU - Pletcher, John M.

AU - Figg, William D.

AU - Yovandich, Jason L.

AU - Creekmore, Stephen P.

PY - 2011/5/5

Y1 - 2011/5/5

N2 - IL-15 uses the heterotrimeric receptor IL-2/IL-15Rβ and the γ chain shared with IL-2 and the cytokine-specific IL-15Rα. Although IL-15 shares actions with IL-2 that include activation of natural killer (NK) and CD8 T cells, IL-15 is not associated with capillary leak syndrome, activation-induced cell death, or with a major effect on the number of functional regulatory T cells. To prepare for human trials to determine whether IL-15 is superior to IL-2 in cancer therapy, recombinant human IL-15 (rhIL-15) was produced under current good manufacturing practices. A safety study in rhesus macaques was performed in 4 groups of 6 animals each that received vehicle diluent control or rhIL-15 at 10, 20, or 50 μg/kg/d IV for 12 days. The major toxicity was grade 3/4 transient neutropenia. Bone marrow examinations demonstrated increased marrow cellularity, including cells of the neutrophil series. Furthermore, neutrophils were observed in sinusoids of enlarged livers and spleens, suggesting that IL-15 mediated neutrophil redistribution from the circulation to tissues. The observation that IL-15 administration was associated with increased numbers of circulating NK and CD8 central and effector-memory T cells, in conjunction with efficacy studies in murine tumor models, supports the use of multiple daily infusions of rhIL-15 in patients with metastatic malignancies.

AB - IL-15 uses the heterotrimeric receptor IL-2/IL-15Rβ and the γ chain shared with IL-2 and the cytokine-specific IL-15Rα. Although IL-15 shares actions with IL-2 that include activation of natural killer (NK) and CD8 T cells, IL-15 is not associated with capillary leak syndrome, activation-induced cell death, or with a major effect on the number of functional regulatory T cells. To prepare for human trials to determine whether IL-15 is superior to IL-2 in cancer therapy, recombinant human IL-15 (rhIL-15) was produced under current good manufacturing practices. A safety study in rhesus macaques was performed in 4 groups of 6 animals each that received vehicle diluent control or rhIL-15 at 10, 20, or 50 μg/kg/d IV for 12 days. The major toxicity was grade 3/4 transient neutropenia. Bone marrow examinations demonstrated increased marrow cellularity, including cells of the neutrophil series. Furthermore, neutrophils were observed in sinusoids of enlarged livers and spleens, suggesting that IL-15 mediated neutrophil redistribution from the circulation to tissues. The observation that IL-15 administration was associated with increased numbers of circulating NK and CD8 central and effector-memory T cells, in conjunction with efficacy studies in murine tumor models, supports the use of multiple daily infusions of rhIL-15 in patients with metastatic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=79955950299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955950299&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-10-311456

DO - 10.1182/blood-2010-10-311456

M3 - Article

C2 - 21385847

AN - SCOPUS:79955950299

VL - 117

SP - 4787

EP - 4795

JO - Blood

JF - Blood

SN - 0006-4971

IS - 18

ER -